Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

Executive Summary 12
Overview on drug delivery industry 12
Oral drug delivery system 12
Injectable drug delivery system 13
Pulmonary drug delivery system 14
Transdermal drug delivery system 15

Chapter 1 Overview of drug delivery industry 18
Summary 18
What is this report about? 19
Methodology 20
Drug delivery overview 21
Role of drug delivery in the pharma landscape 21
Revenue boosters for pharma companies 22
Patent extension and protection from generic competition 23
Reformulation of existing products 24
Optimizing returns on R&D investment 25
Compliance, bioavailability and safety benefits 26
From drug delivery to specialty pharma 28
Markets for drug delivery systems 30
Oral drug delivery system 30
Pulmonary 30
Injectable 30
Transdermal 30
Market dynamics 31

Chapter 2 Oral drug delivery system 34
Summary 34
Synopsis 35
Oral drug delivery technologies 35
Technologies for fast-dissolving and taste-masking pills 35
Controlled oral drug delivery 36
Types of controlled release 36
Dynamics of oral drug delivery market 37
Biovail 39
Key technologies 39
Therapeutic focus 41
Product portfolio and pipeline candidates 41
Recent financial performance 42
Growth strategies 44
Expanding its presence in diverse geographical areas 44
Deriving growth from strategic alliances 44
Deals and alliances 44
SWOT analysis 45
Strengths 46
Weaknesses 46
Opportunities 47
Threats 47
Elan 48
Key technologies 48
NanoCrystal technology 48
OCR technology 49
Therapeutic focus 50
Product portfolio and pipeline candidates 51
Recent financial performance 52
Growth strategies 54
Alzheimer’s disease 54
Pipeline products 54
Deals and alliances 54
SWOT analysis 56
Strengths 56
Weaknesses 57
Opportunities 57
Threats 58
SkyePharma 59
Key technologies 59
Oral drug delivery technologies 59
Inhalation technologies 60
Insoluble drug delivery (IDD) technology 61
Therapeutic focus 62
Products portfolio and pipeline candidates 62
Recent financial performance 63
Growth strategies 65
Focus on building pipeline of products 65
Deals and alliances 66
SWOT analysis 67
Strengths 67
Weaknesses 68
Opportunities 68
Threats 69
Chapter 3 Injectable drug delivery system 72
Summary 72
Synopsis 73
Injectable drug delivery technologies 73
Needleless injection device technology 74
Sustained/controlled release technology 74
PEGylation 74
Therapeutic focus 75
Dynamics of the injectable drug delivery market 75
Alkermes 76
Introduction 76
Key technologies 76
Medisorb injectable technology 76
AIR pulmonary drug delivery technology 77
Therapeutic focus 77
Product portfolio and pipeline candidates 77
Recent financial performance 78
Growth strategies 80
Deals and alliances 81
SWOT analysis 82
Strengths 82
Weaknesses 83
Opportunities 83
Threats 83
Bioject 85
Introduction 85
Key technologies 85
Needle-free injection technology 85
Therapeutic Focus 86
Product portfolio and pipeline candidates 86
Recent financial performance 87
Growth strategies 89
Developing clinical research collaborations 89
Deals and alliances 90
SWOT analysis 91
Strengths 91
Weaknesses 91
Opportunities 92
Threats 92
QLT 93
Key technologies 93
Atrigel drug delivery system 93
PDT 94
Therapeutic focus 94
Product portfolio and pipeline candidates 94
Recent company financials 95
Growth strategies 97
Focus on key therapeutic areas 97
Deals and alliances 98
SWOT analysis 99
Strengths 99
Weaknesses 100
Opportunities 100
Threats 101

Chapter 4 Pulmonary drug delivery system 104
Summary 104
Synopsis 105
Inhaled formulations 105
Therapeutic focus 106
Dynamics of the pulmonary drug delivery market 107
Nektar Therapeutics 108
Key technologies 108
Dry powder pulmonary technology 108
Liquid pulmonary technology 109
PEGylation technology 109
Therapeutic focus 109
Product portfolio and pipeline candidates 110
Recent financial performance 111
Growth strategies 112
Shifting focus from drug delivery to become a specialty pharma company 113
Deals and alliances 113
SWOT analysis 114
Strengths 114
Weaknesses 115
Opportunities 115
Threats 116
Aradigm 118
Key technologies 118
AERx pulmonary drug delivery system 118
Liposomal Formulations 119
Therapeutic focus 119
Product portfolio and pipeline candidates 119
Recent financial performance 120
Growth strategies 122
Deals and alliances 122
SWOT analysis 123
Strengths 123
Weaknesses 123
Opportunities 124
Threats 124
3M 125
Key technologies 125
Pulmonary drug delivery technology 125
Transdermal drug delivery technology 126
Therapeutic focus 126
Product portfolio and pipeline candidates 127
Growth strategies 127
Deals and alliances 128

Chapter 5 Transdermal drug delivery system 132
Summary 132
Synopsis 133
Transdermal drug delivery technologies 133
Passive formulations 134
Active formulations 134
Therapeutic focus 135
Dynamics of the transdermal drug delivery market 135
Antares 137
Key technologies 137
Advanced transdermal delivery 137
Injection devices 138
Easy Tec fast melt oral disintegrating tablets 139
Therapeutic focus 139
Product portfolio and pipeline candidates 139
Recent financial performance 140
Growth strategies 142
Deals and alliances 143
SWOT analysis 145
Strengths 145
Weaknesses 146
Opportunities 147
Threats 148
Noven 150
Key technologies 150
DOT Matrix technology 150
Therapeutic focus 151
Product portfolio and pipeline candidates 152
Recent financial performance 153
Growth strategies 154
Deals and alliances 155
SWOT analysis 155
Strengths 155
Weaknesses 157
Opportunities 158
Threats 158
Alza 159
Key technologies 159
D-Trans 159
E-Trans 160
Macroflux 160
Stealth 160
Alzamer 161
Oros 161
Therapeutic focus 162
Product portfolio and pipeline candidate 162
Deals and alliances 163
SWOT analysis 164
Strengths 164
Weaknesses 165
Opportunities 166
Threats 166
Chapter 6 Conclusion 168
Financials 168
Growth strategies 169
Outlook 172
Glossary 174
Index 175

List of Figures
Figure 1.1: Drug delivery technologies are revenue boosters for pharma companies 22
Figure 1.2: Procardia XL patent expiry 23
Figure 1.3: Cardizem’s reformulation strategy 25
Figure 1.4: Compliance, bioavailability and safety benefits via effectice drug delivery 27
Figure 1.5: Positioning of key drug delivery companies 29
Figure 1.6: Key drug delivery systems market share, 2006 31
Figure 2.7: Biovail financial performance, $m, 2003–2007 43
Figure 2.8: Biovail SWOT analysis 45
Figure 2.9: Elan financial performance, 2003–2007 ($m) 53
Figure 2.10: Elan SWOT analysis 56
Figure 2.11: SkyePharma financial performance, $m, 2003–2007 65
Figure 2.12: SkyePharma SWOT analysis 67
Figure 3.13: Alkermes financial performance, 2003–2007 80
Figure 3.14: Alkermes SWOT analysis 82
Figure 3.15: Bioject financial performance, 2003–2007 ($m) 89
Figure 3.16: Bioject SWOT analysis 91
Figure 3.17: QLT financial performance, 2003–2007 ($m) 97
Figure 3.18: QLT SWOT analysis 99
Figure 4.19: Nektar financial performance, 2003–2007 ($m) 112
Figure 4.20: Nektar SWOT analysis 114
Figure 4.21: Aradigm financial performance, 2003–2007 ($m) 121
Figure 4.22: Aradigm SWOT analysis 123
Figure 5.23: Antares financial performance, 2003-2007 ($m) 142
Figure 5.24: Antares SWOT analysis 145
Figure 5.25: Noven financial performance, 2003-2007 ($m) 154
Figure 5.26: Noven SWOT analysis 155
Figure 5.27: Alza SWOT analysis 164
Figure 6.28: Comparative analysis of key drug delivery companies (I) 170
Figure 6.29: Comparative analysis of key drug delivery companies (II) 171

List of Tables
Table 2.1: Biovail snapshot 39
Table 2.2: Biovail oral marketed products 41
Table 2.3: Biovail oral product sales, 2006–2007 ($m) 41
Table 2.4: Biovail oral product pipeline 42
Table 2.5: Biovail financial performance, 2003–2007 ($m) 43
Table 2.6: Elan snapshot 48
Table 2.7: Elan oral marketed products 51
Table 2.8: Elan NanoCrystal product pipeline 52
Table 2.9: Elan financial performance, 2003–2007 ($m) 53
Table 2.10: SkyePharma snapshot 59
Table 2.11: SkyePharma oral marketed products 62
Table 2.12: Skye Pharma oral product pipeline 63
Table 2.13: SkyePharma financial performance, 2003–2007 64
Table 3.14: Alkermes snapshot 76
Table 3.15: Alkermes injectable marketed products 78
Table 3.16: Alkermes injectable product sales, 2006–2007 ($m) 78
Table 3.17: Alkermes injectable product pipeline 78
Table 3.18: Alkermes financial performance, 2003–2007 ($m) 79
Table 3.19: Bioject snapshot 85
Table 3.20: Bioject injectable marketed products 86
Table 3.21: Bioject injectable product sales, 2006–2007 ($m) 87
Table 3.22: Bioject financial performance, 2003–2007 ($m) 88
Table 3.23: QLT snapshot 93
Table 3.24: QLT injectable marketed products 95
Table 3.25: QLT injectable product sales, 2006–2007 ($m) 95
Table 3.26: QLT injectable product pipeline 95
Table 3.27: QLT financial performance, 2003–2007 ($m) 96
Table 4.28: Nektar snapshot 108
Table 4.29: Nektar pulmonary marketed products 110
Table 4.30: Nektar pulmonary product sales, 2006–2007 ($m) 110
Table 4.31: Nektar pulmonary product pipeline 111
Table 4.32: Nektar financial performance, 2003–2007 ($m) 112
Table 4.33: Aradigm snapshot 118
Table 4.34: Aradigm pulmonary product pipeline 120
Table 4.35: Aradigm financial performance, 2003–2007 ($m) 121
Table 4.36: 3M snapshot 125
Table 4.37: 3M pulmonary marketed products 127
Table 5.38: Antares snapshot 137
Table 5.39: Antares transdermal marketed products 139
Table 5.40: Antares transdermal product pipleine 140
Table 5.41: Antares financial performance, 2003–2007 ($m) 141
Table 5.42: Noven snapshot 150
Table 5.43: Noven transdermal marketed products 152
Table 5.44: Noven transdermal product pipeline 152
Table 5.45: Noven financial performance, 2003–2007 ($m) 153
Table 5.46: Alza snapshot 159
Table 5.47: Alza transdermal marketed products 162